Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $76.29 Consensus Target Price from Brokerages

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) has been assigned a consensus rating of "Buy" from the nine brokerages that are covering the firm, Marketbeat.com reports. Nine investment analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have covered the stock in the last year is $76.29.

AKRO has been the subject of several recent analyst reports. Canaccord Genuity Group boosted their target price on Akero Therapeutics from $56.00 to $73.00 and gave the stock a "buy" rating in a research report on Tuesday, January 28th. HC Wainwright increased their price target on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research report on Monday, March 3rd. Morgan Stanley restated an "overweight" rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Bank of America raised shares of Akero Therapeutics from a "neutral" rating to a "buy" rating and increased their target price for the company from $35.00 to $63.00 in a report on Thursday, January 30th. Finally, Citigroup upped their price target on shares of Akero Therapeutics from $65.00 to $80.00 and gave the company a "buy" rating in a research report on Tuesday, January 28th.

Akero Therapeutics Stock Up 0.3 %

NASDAQ AKRO traded up $0.14 during trading hours on Wednesday, hitting $45.01. The company's stock had a trading volume of 157,821 shares, compared to its average volume of 877,255. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05. The company's 50-day simple moving average is $41.66 and its two-hundred day simple moving average is $37.12. The company has a market capitalization of $3.59 billion, a PE ratio of -12.00 and a beta of -0.12. Akero Therapeutics has a 52 week low of $17.86 and a 52 week high of $58.40.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last issued its quarterly earnings results on Friday, February 28th. The company reported ($0.99) EPS for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.01). Research analysts anticipate that Akero Therapeutics will post -3.99 EPS for the current fiscal year.

Insider Buying and Selling at Akero Therapeutics

In other Akero Therapeutics news, CEO Andrew Cheng sold 30,000 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $52.73, for a total transaction of $1,581,900.00. Following the sale, the chief executive officer now directly owns 686,062 shares in the company, valued at approximately $36,176,049.26. This trade represents a 4.19 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Timothy Rolph sold 6,250 shares of the business's stock in a transaction that occurred on Thursday, April 24th. The shares were sold at an average price of $41.03, for a total transaction of $256,437.50. Following the transaction, the insider now directly owns 169,721 shares of the company's stock, valued at $6,963,652.63. The trade was a 3.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 217,458 shares of company stock worth $9,733,261. 7.94% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Barclays PLC increased its position in Akero Therapeutics by 127.9% in the third quarter. Barclays PLC now owns 127,668 shares of the company's stock worth $3,662,000 after purchasing an additional 71,652 shares during the last quarter. Exome Asset Management LLC bought a new stake in Akero Therapeutics during the third quarter worth approximately $2,212,000. SG Americas Securities LLC raised its position in Akero Therapeutics by 4,022.1% during the fourth quarter. SG Americas Securities LLC now owns 597,993 shares of the company's stock valued at $16,636,000 after purchasing an additional 583,486 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in shares of Akero Therapeutics by 10.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,800 shares of the company's stock valued at $412,000 after purchasing an additional 1,446 shares during the last quarter. Finally, abrdn plc boosted its holdings in shares of Akero Therapeutics by 118.7% in the 4th quarter. abrdn plc now owns 269,782 shares of the company's stock worth $7,505,000 after purchasing an additional 146,424 shares during the period.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.